Somerville, MA, United States of America

Christopher Michael Adams

This inventor holds 25 USPTO granted patents and 17 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in Drug Delivery Systems. Top assignees: Novartis Ag, Other. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Michael Adams. Retrieved from https://idiyas.com/inventor/christopher-michael-adams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 17)

% Patents Active = 44.0

CIPO Patents = 5

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 133(Granted Patents)

Location History:

Verdi, NV (US) (2000 - 2001)
Somerville, MA (US) (2011 - 2019)
Arlington, MA (US) (2017 - 2022)

Company Filing History:

23 out of 3,978

Novartis Ag

patents

2 out of 834,601

Other

patents

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Drug Delivery

Ocular Disease

Guanylate Cyclase Activators

Complement Factor B Inhibitors

Sustained Release

Aqueous Compositions

Organic Compounds

C5A Receptor Modulators

Indane Derivatives

Indole Derivatives

Piperidinyl Compounds

Abrasive Attachments

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433949 - Sustained release delivery systems comprising traceless linkers (2025-10-07),

2. 11389541 - Sustained delivery of angiopoetin-like 3 polypeptides (2022-07-19),

3. 10751417 - Sustained release delivery systems comprising traceless linkers (2020-08-25),

4. 10550102 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2020-02-04),

5. 10537563 - Methods for treating ocular disease using inhibitors of CSF-1R (2020-01-21),

6. 10316020 - Indane derivatives and the use thereof as soluble guanylate cyclase activators (2019-06-11),

7. 10208018 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2019-02-19),

8. 10174006 - Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease (2019-01-08),

9. 10093663 - Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof (2018-10-09),

10. 9957254 - Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2018-05-01),

11. 9765067 - Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2017-09-19),

12. 9682968 - Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof (2017-06-20),

13. 9676728 - 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof (2017-06-13),

14. 9505755 - Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators (2016-11-29),

15. 9475806 - Complement factor B inhibitors and uses there of (2016-10-25),

Title: Innovator Spotlight: Christopher Michael Adams

Introduction:

Christopher Michael Adams, a prolific inventor based in Somerville, MA (US), is making waves in the field of drug delivery systems with his groundbreaking inventions. With an impressive portfolio of 22 patents, Adams has established himself as a leading figure in the industry.

Latest Patents:

Among his latest patents is the innovative "Sustained delivery of angiopoetin-like 3 polypeptides," which focuses on drug delivery systems for delivering biologically active agents with sustained release properties. Another notable invention is the "Sustained release delivery systems comprising traceless linkers," showcasing Adams' expertise in developing cutting-edge pharmaceutical compositions.

Career Highlights:

Currently employed at Novartis AG, Adams continues to drive innovation and push the boundaries of drug delivery technology. His work at Novartis AG reflects his commitment to advancing healthcare through transformative inventions.

Collaborations:

Throughout his career, Adams has collaborated with talented individuals such as Takeru Ehara and Nan Ji, demonstrating his ability to work effectively in multidisciplinary teams. These collaborations have undoubtedly contributed to the success of his innovative projects.

Conclusion:

In conclusion, Christopher Michael Adams stands out as a visionary inventor who is shaping the future of drug delivery systems. His dedication to excellence and pioneering spirit make him a key player in the industry, and his patents are a testament to his ingenuity and passion for innovation.

Profile summary based on public USPTO records.